BioCryst Raises Revenue Outlook To $715 Million To $730 Million As Quarterly Profit Triples
The hereditary angioedema drugmaker held its ORLADEYO forecast and trimmed its adjusted operating expense outlook to $415 million to $425 million.
BioCryst Pharmaceuticals, which develops medicines for hereditary angioedema and other rare diseases, raised its 2026 total revenue forecast to $715 million to $730 million on Wednesday, after third-quarter net income rose to $37.9 million from $12.9 million a year earlier.
Quarter and outlook, by the numbers
Third-quarter revenue was $180.3 million, up 13% from a year earlier, or up 24% excluding European revenue. ORLADEYO, the company's once-daily oral pill that prevents hereditary angioedema attacks, brought in $174.8 million, according to the company's earnings release.
Operating profit was $53.3 million against $29.6 million a year earlier. On an adjusted basis it was $86.5 million against $50.8 million.
The prior total revenue outlook, given on August 5, was $690 million to $715 million. The company attributed the increase mainly to higher licensing revenue from navenibart rights and larger RAPIVAB orders from international partners. ORLADEYO guidance stayed at $625 million to $645 million.
Adjusted operating expense guidance improved to $415 million to $425 million from $420 million to $440 million, which the company tied to progress closing its Birmingham site.
CareMed inventory helped the quarter
Revenue growth benefited from the August switch to CareMed as sole specialty pharmacy partner. CareMed built an initial ORLADEYO inventory, which the company expects to stay relatively stable. ORLADEYO revenue excluding Europe still grew year over year when that inventory build was removed.
The company launched ORLADEYO oral pellets for children aged 2 to under 12 in August. In October the FDA approved the pellets for patients 12 and older, so the drug now comes as a capsule or pellets. CEO Charlie Gayer said the company delivered "continued growth of ORLADEYO and strong profitability."
Birmingham closure and pipeline dates
Birmingham closure work is on track to be substantially complete by year-end. The company expects cash costs of about $10 million and annualized savings of about $30 million to $35 million once fully realized. The quarter's research expenses included impairment and termination charges tied to the closure.
BioCryst also discontinued STAR-0310, the atopic dermatitis program it acquired with Astria Therapeutics, to focus on rare diseases.
Cash, equivalents, restricted cash and investments totaled $376.4 million at September 30, after positive cash flow in the quarter.
BioCryst expects early clinical data for BCX17725 in Netherton syndrome by the end of 2026, and pivotal navenibart results in the third quarter of 2027.